Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

apotheca company - human chorionic gonadotropin (unii: 20ed16gheb) (human chorionic gonadotropin - unii:20ed16gheb) - human chorionic gonadotropin 60 [hp_x] in 1 ml - indications:   supports weight loss by facilitating hormone functions and temporarily decreasing appetite. indications:   supports weight loss by facilitating hormone functions and temporarily decreasing appetite.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

organon llc - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins. - prior hypersensitivity reactions to human gonadotropins, including hcg, or any of the excipients (see adverse reactions). - high serum fsh, indicating primary gonadal failure in women. - presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). - tumors of the hypothalamus or pituitary gland and ovary, breast, or uterus in females and breast or prostate in males. - malformations of the reproductive organs incompatible with pregnancy. - fibroid tumors of the uterus incompatible with pregnancy. - abnormal vaginal bleeding of undetermined origin.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - choriogonadotropin alfa 250ug; choriogonadotropin alfa 250ug - solution for injection - 250 mcg/0.5ml - active: choriogonadotropin alfa 250ug excipient: mannitol methionine phosphoric acid poloxamer sodium hydroxide water for injection active: choriogonadotropin alfa 250ug excipient: dibasic sodium phosphate dihydrate mannitol methionine phosphoric acid poloxamer sodium hydroxide sodium phosphate water for injection - anovulatory or oligo-ovulatory women: ovidrel is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

merck europe b.v. - choriogonadotropin alfa - anovulation; reproductive techniques, assisted; infertility, female - sex hormones and modulators of the genital system, - ovitrelle is indicated in the treatment of:women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (ivf): ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth;anovulatory or oligo-ovulatory women: ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

ax pharmaceutical corp - human chorionic gonadotropin (unii: 20ed16gheb) (chorionic gonadotropin - unii:20ed16gheb) - human chorionic gonadotropin 990000 [iu] in 1000000 [iu]

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

apotheca company - human chorionic gonadotropin (unii: 20ed16gheb) (human chorionic gonadotropin - unii:20ed16gheb) - human chorionic gonadotropin 200 [hp_c] in 1 ml - indications:   supports weight loss by regulating male and female hormone functions and also suppressing ravenous appetite.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

apotheca company - human chorionic gonadotropin (unii: 20ed16gheb) (human chorionic gonadotropin - unii:20ed16gheb) - human chorionic gonadotropin 34 [hp_c] in 1 ml - indications:   supports weight loss by regulating male and female hormone functions and also by suppressing ravenous appetite. indications: supports weight loss by regulating male and female hormone functions and also by suppressing ravenous appetite.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

apotheca company - human chorionic gonadotropin (unii: 20ed16gheb) (human chorionic gonadotropin - unii:20ed16gheb) - human chorionic gonadotropin 60 [hp_x] in 1 ml

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - choriogonadotropin alfa, quantity: 250 microgram - injection, solution - excipient ingredients: methionine; mannitol; poloxamer; phosphoric acid; water for injections; sodium hydroxide - ovidrel is indicated in the treatment of (i) women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (ivf): ovidrel is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. (ii) anovulatory or oligo-ovulatory women: ovidrel is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

a-s medication solutions - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins. - prior hypersensitivity reactions to human gonadotropins, including hcg, or any of the excipients (see adverse reactions). - high serum fsh, indicating primary gonadal failure in women. - presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). - tumors of the hypothalamus or pituitary gland and ovary, breast, or uterus in females and breast or prostate in males. - malformations of the reproductive organs incompatible with pregnancy. - fibroid tumors of the uterus incompatible with pregnancy. - abnormal vaginal bleeding of undetermined origin.